The effectiveness of anti-osteoporotic therapy with alendronate in geriatric hip fracture patients

Tóm tắt

Objective: To evaluate the difference of bone mineral density and serum concentration of osteocalcin, CTX in geriatric hip fracture patients after 12 months of anti-osteoporotic therapy with  alendronate. Subject and method: 60 patients ≥ 60 years old in 108 Military Central Hospital and 103 Military Hospital, were divided in two groups: 30 hip fracture patients with osteoporosis, treated with alendronate in 12 consecutive months, and 30 non-hip fracture people as control group. Patients were evaluated by bone mineral density (BMD) measurement (DEXA technique, Hologic machine) and concentration of serum osteocalcin, CTX, before and after 12 months of alendronate treatment. Result: After 12 months of alendronate (Fosamax) treatment, the lumbar mean BMD increased (∆) 0.060 ± 0.040 (g/cm2) and there were 30% (9) patients with BMD improvement, p<0.05, the hip mean BMD also increased (∆) 0.080 ± 0.061 (g/cm2) and there were 33.3% (10) patients with BMD improvement, p<0.01. The decreases in serum concentration of osteocalcin, CTX, and patient rates were 1.47 ± 8.13ng/ml, 20% (6 pts) (p>0.05), 0.16 ± 0.2ng/ml, 33.3% (10 patients) (p<0.05), respectively. Conclusion: The geriatric hip fracture patients with osteoporosis had good outcome in term of bone mineral density and CTX serum concentration after 12 month treatment with alendronate.

Keywords: Hip fracture, bone mineral density, osteocalcin, CTX, alendronate.